|
WO1996029350A1
(en)
|
1995-03-20 |
1996-09-26 |
Sumitomo Electric Industries, Ltd. |
MONOCLONAL ANTIBODY REACTING SPECIFICALLY WITH Fas LIGAND AND PROCESS FOR PRODUCING THE SAME
|
|
WO1996040041A2
(en)
*
|
1995-06-07 |
1996-12-19 |
Chiron Corporation |
Antibodies to fas antigen capable of inhibiting apoptosis
|
|
US6096312A
(en)
*
|
1995-06-30 |
2000-08-01 |
Mochida Pharmaceutical Co., Ltd. |
Agent for suppressing a reduction of CD4+ lymphocytes
|
|
JPH09124509A
(ja)
*
|
1995-10-27 |
1997-05-13 |
Sumitomo Electric Ind Ltd |
肝炎治療剤
|
|
DE19544333C2
(de)
*
|
1995-11-28 |
1998-12-10 |
Deutsches Krebsforsch |
Verfahren zur Beurteilung der Aktivität von Arzneistoffen
|
|
AU2814897A
(en)
*
|
1996-04-25 |
1997-11-12 |
T Cell Sciences, Inc. |
Method of isolating regulators of t cell activation
|
|
GB9703276D0
(en)
*
|
1997-02-17 |
1997-04-09 |
Screaton Gavin R |
Materials and methods relating to the protection of useful immune cells
|
|
AU1288099A
(en)
*
|
1997-10-30 |
1999-05-24 |
Cornell Research Foundation Inc. |
A method of inhibiting an immune response to a recombinant vector
|
|
EP1447093A1
(en)
|
2003-02-14 |
2004-08-18 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries
|
|
CA2520138C
(en)
|
2003-03-26 |
2017-05-23 |
Apogenix Gmbh |
Improved fc fusion proteins
|
|
ES2523992T3
(es)
|
2006-12-28 |
2014-12-03 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
La neutralización de la actividad de CD95 bloquea la invasión de células de glioblastoma in vivo
|
|
EP2540740B1
(en)
|
2008-06-17 |
2014-09-10 |
Apogenix GmbH |
Multimeric TNF receptors
|
|
US11369572B2
(en)
*
|
2009-07-21 |
2022-06-28 |
Queen Mary & Westfield College |
Fas (Apo-1,CD95) targeted platforms for intracellular drug delivery
|
|
RU2652348C2
(ru)
|
2012-07-18 |
2018-04-25 |
Аподжиникс Аг |
Ингибиторы сигнального пути cd95 для лечения мдс
|
|
EP3076179A1
(en)
|
2015-03-30 |
2016-10-05 |
Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts |
Diagnosis and treatment of low grade gliomas
|
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
|
CA3049165A1
(en)
|
2017-01-06 |
2018-07-12 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
|
|
BR112019013940A2
(pt)
|
2017-01-06 |
2020-02-11 |
Iovance Biotherapeutics, Inc. |
Método de tratar um câncer com uma população de linfócitos infiltrantes de tumor, processo para preparação de uma população de linfócitos infiltrantes de tumor, população de linfócitos infiltrantes de tumor, e, composição farmacêutica.
|
|
US20200224161A1
(en)
|
2017-05-10 |
2020-07-16 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
EP3714041A1
(en)
|
2017-11-22 |
2020-09-30 |
Iovance Biotherapeutics, Inc. |
Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
|
|
EP3724885A2
(en)
|
2017-12-15 |
2020-10-21 |
Iovance Biotherapeutics, Inc. |
Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
|
|
CA3090795A1
(en)
|
2018-02-13 |
2019-08-22 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
|
|
US20220133795A1
(en)
|
2019-03-01 |
2022-05-05 |
Iovance Biotherapeutics, Inc. |
Expansion of Tumor Infiltrating Lymphocytes From Liquid Tumors and Therapeutic Uses Thereof
|
|
CA3134144A1
(en)
|
2019-03-29 |
2020-10-08 |
Myst Therapeutics, Llc |
Ex vivo methods for producing a t cell therapeutic and related compositions and methods
|
|
CA3162703A1
(en)
|
2019-11-27 |
2021-06-03 |
Myst Therapeutics, Llc |
Method of producing tumor-reactive t cell composition using modulatory agents
|
|
JP7817937B2
(ja)
|
2020-02-27 |
2026-02-19 |
ターンストーン バイオロジクス コーポレイション |
腫瘍反応性ｔ細胞のエクスビボ富化および増大のための方法ならびに関連するその組成物
|
|
WO2024098024A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
WO2026044087A1
(en)
|
2024-08-21 |
2026-02-26 |
Shape Therapeutics Inc. |
Increased cellular stability for aav production
|
|
WO2026073032A1
(en)
|
2024-09-27 |
2026-04-02 |
Shape Therapeutics Inc. |
Constructs for improved aav production
|